Akebia Therapeutics (AKBA) Competitors $3.19 0.00 (0.00%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$3.20 +0.02 (+0.47%) As of 08/22/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AKBA vs. MENS, KYMR, SRRK, BHC, XENE, AMRX, HCM, RARE, NAMS, and MORShould you be buying Akebia Therapeutics stock or one of its competitors? The main competitors of Akebia Therapeutics include Jyong Biotech (MENS), Kymera Therapeutics (KYMR), Scholar Rock (SRRK), Bausch Health Cos (BHC), Xenon Pharmaceuticals (XENE), Amneal Pharmaceuticals (AMRX), HUTCHMED (HCM), Ultragenyx Pharmaceutical (RARE), NewAmsterdam Pharma (NAMS), and MorphoSys (MOR). These companies are all part of the "pharmaceutical products" industry. Akebia Therapeutics vs. Its Competitors Jyong Biotech Kymera Therapeutics Scholar Rock Bausch Health Cos Xenon Pharmaceuticals Amneal Pharmaceuticals HUTCHMED Ultragenyx Pharmaceutical NewAmsterdam Pharma MorphoSys Jyong Biotech (NASDAQ:MENS) and Akebia Therapeutics (NASDAQ:AKBA) are both pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk. Is MENS or AKBA more profitable? Jyong Biotech has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -17.91%. Company Net Margins Return on Equity Return on Assets Jyong BiotechN/A N/A N/A Akebia Therapeutics -17.91%N/A -13.47% Which has higher earnings and valuation, MENS or AKBA? Jyong Biotech has higher earnings, but lower revenue than Akebia Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJyong BiotechN/AN/AN/AN/AN/AAkebia Therapeutics$160.18M5.28-$69.41M-$0.17-18.76 Do insiders and institutionals have more ownership in MENS or AKBA? 33.9% of Akebia Therapeutics shares are held by institutional investors. 3.0% of Akebia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts rate MENS or AKBA? Akebia Therapeutics has a consensus target price of $6.75, indicating a potential upside of 111.60%. Given Akebia Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Akebia Therapeutics is more favorable than Jyong Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jyong Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Akebia Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media refer more to MENS or AKBA? In the previous week, Akebia Therapeutics had 1 more articles in the media than Jyong Biotech. MarketBeat recorded 7 mentions for Akebia Therapeutics and 6 mentions for Jyong Biotech. Akebia Therapeutics' average media sentiment score of 0.81 beat Jyong Biotech's score of 0.44 indicating that Akebia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jyong Biotech 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Akebia Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAkebia Therapeutics beats Jyong Biotech on 9 of the 11 factors compared between the two stocks. Get Akebia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKBA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKBA vs. The Competition Export to ExcelMetricAkebia TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$845.81M$2.54B$5.83B$9.78BDividend YieldN/A1.67%4.40%4.05%P/E Ratio-18.765.4322.8124.74Price / Sales5.28752.08473.17122.93Price / CashN/A179.1038.0259.36Price / Book29.005.939.536.60Net Income-$69.41M$31.83M$3.26B$265.65M7 Day Performance-1.85%1.89%2.14%2.02%1 Month Performance-20.45%1.33%2.81%-0.32%1 Year Performance108.50%8.84%30.70%19.06% Akebia Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKBAAkebia Therapeutics3.9393 of 5 stars$3.19flat$6.75+111.6%+117.0%$845.81M$160.18M-18.76430Analyst RevisionMENSJyong BiotechN/A$41.50-7.2%N/AN/A$3.16BN/A0.0031News CoverageKYMRKymera Therapeutics2.7172 of 5 stars$43.62+2.3%$59.11+35.5%-3.8%$3.12B$47.07M-12.57170SRRKScholar Rock4.5851 of 5 stars$31.52+0.4%$45.14+43.2%+294.8%$3.03B$33.19M-10.83140News CoverageAnalyst ForecastBHCBausch Health Cos4.2185 of 5 stars$8.02-3.8%$9.00+12.2%+29.7%$2.97B$9.63B30.8520,700Trending NewsAnalyst RevisionXENEXenon Pharmaceuticals2.0522 of 5 stars$37.82-1.1%$53.20+40.7%+0.5%$2.92B$9.43M-10.65210News CoverageOptions VolumeAMRXAmneal Pharmaceuticals3.3101 of 5 stars$9.26-2.0%$11.60+25.3%+19.1%$2.91B$2.79B926.938,100News CoveragePositive NewsInsider TradeHCMHUTCHMED2.6635 of 5 stars$16.43-0.1%$28.00+70.4%-10.0%$2.87B$630.20M0.001,811RAREUltragenyx Pharmaceutical4.721 of 5 stars$29.70+0.0%$81.50+174.4%-47.2%$2.86B$560.23M-5.371,294News CoverageNAMSNewAmsterdam Pharma3.4293 of 5 stars$25.40+1.3%$41.20+62.2%+51.2%$2.86B$45.56M-15.684MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730Positive News Related Companies and Tools Related Companies MENS Alternatives KYMR Alternatives SRRK Alternatives BHC Alternatives XENE Alternatives AMRX Alternatives HCM Alternatives RARE Alternatives NAMS Alternatives MOR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKBA) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akebia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access